Phosplatin Therapeutics is harnessing immunogenic cell death (ICD) as an alternative mechanism to existing cancer immunotherapy strategies. PT-112, Phosplatin’s lead ICD inducer, is in phase 2 ...

Photoimmunotherapy is an innovative cancer treatment that combines phototherapy with immunotherapy to selectively target and ...

Photoimmunotherapy is an innovative cancer treatment that combines phototherapy with immunotherapy to selectively target and ...

Photoimmunotherapy with the M@P nanoplatform offers a novel approach, triggering cancer cell death and boosting immune ...

Personalized vaccine targets key driver mutations and induces antitumor immunity in fully resected high-risk clear cell renal cell carcinoma. (HealthDay News) — Neoantigen-targeting personalized ...

Developing low side-effect pyroptosis and ferroptosis inducers for cancer therapy, especially dual function inducers, is a ...

THURSDAY, Feb. 6, 2025 (HealthDay News) -- Neoantigen-targeting personalized cancer vaccines (PCVs) are highly immunogenic in high-risk clear cell renal cell carcinoma (RCC) and can target key driver ...

Luminescent gold nanoparticles (L-AuNPs) represent a novel class of luminescent nanomaterials that have attracted ...

The team, led by Martin McIntosh, Ph.D., head of the Computational Biology Program at Fred Hutch, is using high-throughput technology and emerging public data resources to help identify hundreds of ...